Target Price | GBP141.09 |
Price | GBP109.22 |
Potential | 29.18% |
Number of Estimates | 28 |
28 Analysts have issued a price target AstraZeneca 2026 . The average AstraZeneca target price is GBP141.09. This is 29.18% higher than the current stock price. The highest price target is GBP189.00 73.05% , the lowest is GBP68.65 37.15% . | |
A rating was issued by 34 analysts: 28 Analysts recommend AstraZeneca to buy, 6 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the AstraZeneca stock has an average upside potential 2026 of 29.18% . Most analysts recommend the AstraZeneca stock at Purchase. |
30 Analysts have issued a sales forecast AstraZeneca 2025 . The average AstraZeneca sales estimate is GBP44.2b . This is 5.08% higher than the revenue of the last 12 months(TTM). The highest sales forecast is GBP47.1b 12.22% , the lowest is GBP39.2b 6.64% .
This results in the following potential growth metrics:
2024 | GBP40.2b | 18.03% |
---|---|---|
2025 | GBP44.2b | 9.80% |
2026 | GBP46.9b | 6.26% |
2027 | GBP49.6b | 5.74% |
2028 | GBP51.7b | 4.18% |
2029 | GBP55.3b | 6.97% |
2030 | GBP60.1b | 8.61% |
2031 | GBP62.7b | 4.45% |
2032 | GBP63.0b | 0.42% |
26 Analysts have issued an AstraZeneca EBITDA forecast 2025. The average AstraZeneca EBITDA estimate is GBP16.0b . This is 21.66% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is GBP20.1b 52.58% , the lowest is GBP12.1b 8.47% .
This results in the following potential growth metrics and future EBITDA Margins:
2024 | GBP12.3b | 29.46% |
---|---|---|
2025 | GBP16.0b | 30.18% |
2026 | GBP17.7b | 10.39% |
2027 | GBP19.2b | 8.79% |
2028 | GBP20.3b | 5.57% |
2029 | GBP23.1b | 13.91% |
2030 | GBP27.3b | 17.78% |
2031 | GBP29.4b | 7.70% |
2032 | GBP29.9b | 1.90% |
2024 | 30.60% | 9.68% |
---|---|---|
2025 | 36.28% | 18.55% |
2026 | 37.69% | 3.89% |
2027 | 38.78% | 2.89% |
2028 | 39.30% | 1.34% |
2029 | 41.85% | 6.49% |
2030 | 45.38% | 8.43% |
2031 | 46.80% | 3.13% |
2032 | 47.49% | 1.47% |
28 AstraZeneca Analysts have issued a net profit forecast 2025. The average AstraZeneca net profit estimate is GBP10.7b . This is 72.63% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is GBP11.9b 93.65% , the lowest is GBP8.6b 39.94% .
This results in the following potential growth metrics and future Net Margins:
2024 | GBP5.2b | 18.14% |
---|---|---|
2025 | GBP10.7b | 103.55% |
2026 | GBP12.1b | 13.40% |
2027 | GBP13.3b | 9.77% |
2028 | GBP14.4b | 8.66% |
2029 | GBP16.2b | 12.50% |
2030 | GBP17.8b | 9.81% |
2031 | GBP16.4b | 8.08% |
2032 | GBP15.3b | 6.32% |
2024 | 13.01% | 0.09% |
---|---|---|
2025 | 24.12% | 85.39% |
2026 | 25.74% | 6.72% |
2027 | 26.72% | 3.81% |
2028 | 27.87% | 4.30% |
2029 | 29.31% | 5.17% |
2030 | 29.63% | 1.09% |
2031 | 26.08% | 11.98% |
2032 | 24.33% | 6.71% |
28 Analysts have issued a AstraZeneca forecast for earnings per share. The average AstraZeneca EPS is GBP6.87 . This is 73.92% higher than earnings per share in the financial year 2024. The highest EPS forecast is GBP7.70 94.94% , the lowest is GBP5.57 41.01% .
This results in the following potential growth metrics and future valuations:
2024 | GBP3.35 | 18.37% |
---|---|---|
2025 | GBP6.87 | 105.07% |
2026 | GBP7.79 | 13.39% |
2027 | GBP8.55 | 9.76% |
2028 | GBP9.29 | 8.65% |
2029 | GBP10.45 | 12.49% |
2030 | GBP11.48 | 9.86% |
2031 | GBP10.55 | 8.10% |
2032 | GBP9.89 | 6.26% |
Current | 27.65 | 31.06% |
---|---|---|
2025 | 15.94 | 42.50% |
2026 | 14.05 | 11.86% |
2027 | 12.80 | 8.90% |
2028 | 11.78 | 7.97% |
2029 | 10.47 | 11.12% |
2030 | 9.54 | 8.88% |
2031 | 10.38 | 8.81% |
2032 | 11.08 | 6.74% |
Based on analysts' sales estimates for 2025, the AstraZeneca stock is valued at an EV/Sales of 4.31 and an P/S ratio of 3.88 .
This results in the following potential growth metrics and future valuations:
Current | 4.50 | 24.11% |
---|---|---|
2025 | 4.31 | 4.79% |
2026 | 4.06 | 5.89% |
2027 | 3.84 | 5.43% |
2028 | 3.68 | 4.01% |
2029 | 3.44 | 6.52% |
2030 | 3.17 | 7.92% |
2031 | 3.04 | 4.26% |
2032 | 3.02 | 0.42% |
Current | 4.04 | 25.01% |
---|---|---|
2025 | 3.88 | 4.83% |
2026 | 3.65 | 5.90% |
2027 | 3.45 | 5.43% |
2028 | 3.31 | 4.01% |
2029 | 3.10 | 6.51% |
2030 | 2.85 | 7.92% |
2031 | 2.73 | 4.26% |
2032 | 2.72 | 0.42% |
Analyst | Rating | Action | Date |
---|---|---|---|
Deutsche |
➜
Hold
|
Unchanged | Jul 30 2025 |
Shore Capital |
➜
Buy
|
Unchanged | Jul 29 2025 |
Berenberg Bank |
➜
Buy
|
Unchanged | Jul 08 2025 |
Deutsche |
➜
Hold
|
Unchanged | Jul 08 2025 |
Berenberg Bank |
➜
Buy
|
Unchanged | May 16 2025 |
Shore Capital |
➜
Buy
|
Unchanged | Apr 29 2025 |
Berenberg Bank |
➜
Buy
|
Unchanged | Mar 26 2025 |
Analyst Rating | Date |
---|---|
Unchanged
Deutsche:
➜
Hold
|
Jul 30 2025 |
Unchanged
Shore Capital:
➜
Buy
|
Jul 29 2025 |
Unchanged
Berenberg Bank:
➜
Buy
|
Jul 08 2025 |
Unchanged
Deutsche:
➜
Hold
|
Jul 08 2025 |
Unchanged
Berenberg Bank:
➜
Buy
|
May 16 2025 |
Unchanged
Shore Capital:
➜
Buy
|
Apr 29 2025 |
Unchanged
Berenberg Bank:
➜
Buy
|
Mar 26 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.